We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Innovent Biologics’ Humira Biosimilar Earns Chinese Approval
Innovent Biologics’ Humira Biosimilar Earns Chinese Approval
China’s National Medical Products Administration has approved Innovent Biologics’ Humira biosimilar Sulinno (adalimumab injection) for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis.